Table 1.
Demographic and diagnostic factors for patients at diagnosis.
| Median (range)/n (%) | |
|---|---|
| Patient demographics | |
| Age (years) | 40 (19–79) |
| Gender (% female) | 15 (68%) |
| Ethnicity (% caucasian) | 18 (82%) |
| Biochemical parameters at diagnosis | |
| Platelets (x109/L) | 323 (138–582) |
| Alanine aminotransferase (U/L) | 137 (47–518) |
| Aspartate aminotransferase (U/L) | 175 (19–1,208) |
| Bilirubin (μmol/L) | 15 (6–476) |
| Albumin (g/L) | 40 (23–46) |
| International normalised ratio | 1.0 (0.9–1.7) |
| Immunological parameters at diagnosis | |
| IgG (g/L) | 23 (10–45) |
| Antinuclear antibody positivity | 10/17 (59%) |
| Anti-smooth muscle antibody positivity | 13/16 (81%) |
| Prognostic scoring at diagnosis | |
| Simplified autoimmune hepatitis score | 6 (2–8) |
| Model for end-stage liver disease score | 8 (5–25) |
| Metavir fibrosis score | n = 18 |
| Stage 0 | 4 (22%) |
| Stage 1 | 2 (11%) |
| Stage 2 | 3 (17%) |
| Stage 3 | 6 (33%) |
| Stage 4 | 3 (17%) |
| Child-Pugh score for stage 4 fibrosis | n = 3 |
| A | 2 (67%) |
| B | 0 (0%) |
| C | 1 (33%) |